INFLARX NV (IFRX)
NL0012661870 - Common Stock
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by...
IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023
IFRX stock results show that InflaRx missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips InflaRx (NASDAQ:IFRX) just reported results for the fourth quarter of 2023.Infl...
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and...
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by...
InflaRx Appoints Jan Medina as Head of Investor Relations
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by...
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined...
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today!
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part...
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and tolerability with no signals of concern over entire...
EU regulators accept InflaRX vilobelimab application for review (NASDAQ:IFRX)
German biotech InflaRx (IFRX) said that the European regulators have accepted its Marketing Authorization Application for review for its drug vilobelimab. Read more here.
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase...
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States ...
InflaRx N.V. gets new chief medical officer (NASDAQ:IFRX)
clinical-stage biopharmaceutical company InflaRx N.V. (IFRX) appoints Dr. Camilla Chong as Chief Medical Officer ((CMO)) of InflaRx, effective July 1, 2023. Dr
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical...
InflaRx launches vilobelimab for severe COVID (NASDAQ:IFRX)
InflaRx (IFRX) has launched Gohibic (vilobelimab), its treatment for critically ill COVID-19 hospitalized patients. Read more here.
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
Gohibic is now commercially available for hospitals in the U.S.Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for...
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19...
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing...
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing...
InflaRx Announces Public Offering of Ordinary Shares
JENA, Germany, April 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing...
PXD, TGTX and EH among pre-market gainers
OncoSec Medical (ONCS) +65%. GlucoTrack (GCTK) +29%
Why InflaRx Stock Skyrocketed This Week
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.